ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a Phase III clinical study for its investigational drug timdarpacept (IMM01). IMM01 is an SIRPαFc fusion protein that is being studied for use in combination with azacitidine as a first-line treatment for chronic myelomonocytic leukemia (CMML).
Developed by ImmuneOnco using its proprietary “mAb-Trap” technology platform, IMM01 boasts a dual mechanism of action and has exhibited potent anti-tumor activity. Characterized by its unique molecular design, IMM01 has shown a favorable safety profile and a proven capacity to activate macrophages. Prior to this, the company had already obtained clinical trial approval from the NMPA for the treatment of classic Hodgkin’s lymphoma (cHL) and high-risk myelodysplastic syndrome (HRMDS) for Phase III studies.- Flcube.com
